



Divi's Laboratories Limited

Date.25th May, 2019

To
The Secretary
National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex, Bandra (East)
MUMBAI – 400 051

To
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
MUMBAI – 400 001

Stock Code: DIVISLAB

Stock Code: 532488

Dear Sir/ Madam,

Sub: Audited financial results for the year ended 31st March 2019

Ref: Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Further to our letter dated 13th May, 2019, we would like to inform that the Board of Directors of the Company at its meeting held on Saturday, 25th May 2019 has approved the Audited Financial Results for the quarter and year ended 31st March, 2019. Board has recommended dividend @ 800% i.e Rs. 16/- per equity share of face value Rs. 2/- each for the financial year 2018-19, subject to approval of the members at the ensuing Annual General Meeting (AGM). The dividend on Equity Shares, shall be credited/ dispatched within 30 (thirty) days from the conclusion of the AGM, the date of which will be intimated in due course.

In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following:

1. Audited Standalone Financial Results for the quarter and year ended 31st March 2019.
2. Audited Consolidated Financial Results for the year ended 31st March 2019.
3. Auditors' Report on the Standalone and Consolidated Financial Results for the year.
4. Declaration regarding Audit Reports with unmodified opinion.
5. Press Release on the Financial Results of the Company.

The Board meeting commenced at 11:00 Hrs and concluded at 14:45 Hrs

This is for your information and records.

Thanking You,
Yours faithfully,

For Divi's Laboratories Limited


P V Lakshmi Rajani
Company Secretary



“An ISO-9001, ISO-14001 and OHSAS-18001 Triple certified company”

Regd. Off. : Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, INDIA.

Tel : 91-40-2378 6300, Fax : 91-40-2378 6460, CIN : L24110TG1990PLC011854


E-mail : mail@divislaboratories.com, Website : www.divislaboratories.com

DIVI'S LABORATORIES LIMITED

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2019

(₹. in lakhs)

	Particulars	Quarter ended			Year ended	
		31.03.2019	31.12.2018	31.03.2018	31.03.2019	31.03.2018
		(Audited)*	(Unaudited)	(Audited)*	(Audited)	(Audited)
1	Revenue from operations	125643	134292	108795	487966	383723
2	Other Income	4173	3456	4817	15658	11248
3	Total Revenue from Operations (inclusive of excise duty) (1+2)	129816	137748	113612	503624	394971
4	Expenses					
	a) Cost of materials consumed	57718	55157	48071	208205	152428
	b) Purchase of stock-in-trade	0	0	0	0	0
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(7422)	(7138)	(7308)	(24422)	(1938)
	d) Employee benefits expense	13828	13645	12577	53072	44627
	e) Depreciation and amortization expense	4234	4248	3879	16881	14242
	f) Finance Costs	10	252	(17)	350	133
	g) Other Expenses	20410	20295	16805	66215	63543
	Total expenses	88778	86459	74007	320301	273035
5	Profit before exceptional Items and tax (3-4)	41038	51289	39605	183323	121936
6	Exceptional items	0	0	0	0	0
7	Profit before Tax (5-6)	41038	51289	39605	183323	121936
8	Tax Expense					
	a) Current Tax	10924	12994	12261	47245	28713
	b) Deferred Tax	1179	346	1184	2813	6265
	Total Tax Expense	12103	13340	13445	50058	34978
9	Net Profit for the period (7-8)	28935	37949	26160	133265	86958
10	Other Comprehensive Income: Items that will not be reclassified to Profit or Loss:					
	-Remeasurements of post-employment benefit obligations	71	23	233	141	94
	Income tax relating to OCI	(16)	(7)	(55)	(36)	(27)
	Total other comprehensive Income	55	16	178	105	67
11	Total comprehensive Income for the period (9+10)	28990	37965	26338	133370	87025
12	Paid-up Equity Share Capital (Face Value: Rs.2 per share)	5309	5309	5309	5309	5309
13	Other Equity				692022	590656
14	Earnings per Share (of Rs.2/- each) (not annualized)					
	a) Basic (₹.)	10.90	14.29	9.85	50.20	32.76
	b) Diluted (₹.)	10.90	14.29	9.85	50.20	32.76




Statement of Assets and Liabilities

(₹. in lakhs)

	Particulars	STANDALONE	
		As At	
		31.03.2019	31.03.2018
		Audited	Audited
A	ASSETS		
1	Non-current assets		
	Property, plant and equipment	208339	198933
	Capital work-in-progress	49191	11976
	Intangible assets	405	655
	Financial assets		
	a) Investments	55462	737
	b) Loans	3404	3394
	Income Tax assets (net)	1928	881
	Other non-current assets	20540	8811
	Sub-total: Non-current assets	339269	225387
2	Current assets		
	Inventories	166318	128139
	Financial assets		
	a) Investments	139834	188929
	b) Trade receivables	128224	111211
	c) Cash and cash equivalents	294	417
	d) Bank balances other than c) above	10226	8731
	e) Loans	11	1486
	f) Other financial assets	135	948
	Other current assets	19707	15530
	Sub-total: Current assets	464749	455391
	TOTAL ASSETS	804018	680778
B	EQUITY AND LIABILITIES		
1	Equity:		
	Share Capital	5309	5309
	Other Equity		
	a) Reserves and Surplus	692022	590656
	Sub-total: Shareholders' funds	697331	595965
2	Liabilities:		
	Non-current liabilities		
	Provisions	1317	1495
	Deferred tax liabilities (net)	22118	19269
	Sub-total: Non-current liabilities	23435	20764
3	Current Liabilities		
	Financial liabilities		
	a) Borrowings	10560	6311
	b) Trade payables	48331	40565
	c) Other financial liabilities	6289	2233
	Provisions	111	94
	Other current liabilities	17961	14846
	Sub-total: Current liabilities	83252	64049
	Total Liabilities	106687	84813
	TOTAL EQUITY AND LIABILITIES	804018	680778

NOTES:

- The above audited standalone results for the quarter and year ended 31st March 2019, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 25th May, 2019 and the same have been audited by the Statutory auditors in compliance with regulation 33 of SEBI (Listing of Obligation and Disclosure Requirement) Regulation 2015. The Statutory Auditors' report contains no qualification.
- The Company is engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates and the same constitutes a single reportable business segment as per Ind AS 108.
- These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 read with the relevant rules thereunder and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.



4. The Ministry of Corporate Affairs (MCA) on 28th March 2018 notified Ind AS 115 "Revenue from contracts with customers" as part of the Companies (Indian Accounting Standards) Amendment Rules, 2018. The new Standard is effective for reporting periods beginning on or after 1st April 2018. The adoption of the standard did not have any material impact to the financial results of the company.
5. *Figures for the quarter ended 31.03.2019 and corresponding quarter ended 31.03.2018 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures upto the third quarter of the respective financial years.
6. Post implementation of Goods and Service Tax (GST) effective from 1st July, 2017, revenue is reported net of GST as per Ind AS 18/115. Revenue, however, is reported inclusive of excise duty for a part of the year ended 31st March, 2018. Had the previously reported revenue been shown net of excise duty, comparative revenue of the company would have been as under:

(₹. in lakhs)

Particulars	Year Ended	
	31.03.2019	31.03.2018
	(Audited)	(Audited)
Revenue from operations (net of excise duty)	487966	381735

7. The Board of Directors of the company has recommended a dividend of Rs.16/- per equity share of Rs.2 each (i.e., 800%), subject to approval of members.
8. Details of forex gain/loss are given below:

(₹. in lakhs)

	Quarter ended			Year Ended	
	31.03.2019	31.12.2018	31.03.2018	31.03.2019	31.03.2018
	(Audited)*	(Unaudited)	(Audited)*	(Audited)	(Audited)
Forex gain/ (loss)	(743)	(4112)	2297	3092	2460

Forex gain has been included in Other Income and loss has been included in Other Expenses.

9. Figures for the previous year/period have been reclassified/ regrouped wherever necessary to conform to current year's classification.

Place: Hyderabad
Date: 25-05-2019



for Divi's Laboratories Limited

(Signature)
Dr. Murali K. Divi
Chairman & Managing Director



Price Waterhouse Chartered Accountants LLP

The Board of Directors
Divi's Laboratories Limited
Divi Towers, 1-72/23(P)/Divis/303,
Cyber Hills, Gachibowli,
Hyderabad- 500 032

Independent Auditor's Report on the Statement of standalone financial results

1. We have audited the accompanying Statement containing the annual audited standalone financial results of Divi's Laboratories Limited (the "Company") for the year ended March 31, 2019 together with the notes thereon (hereinafter referred to as the "Statement"), which we have signed under reference to this report.

Management's Responsibility for the standalone financial results

2. Management is responsible for the preparation of the accompanying Statement. The Management is also responsible for the preparation of the annual statutory financial statements in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 (the "accounting principles generally accepted in India"), basis which the above Statement containing the annual audited standalone financial results has been prepared. The responsibility includes the design, implementation and maintenance of internal control relevant to the preparation of the Statement that is free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

3. Our responsibility is to express an opinion on the Statement based on our audit. We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 ("the Act") and other applicable authoritative pronouncements issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.
4. An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the Statement. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditors consider internal control relevant to the entity's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by Management, as well as evaluating the overall presentation of the Statement.
5. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



Price Waterhouse Chartered Accountants LLP, Plot No. 77/A, 8-2-624/A/1, 3rd Floor, Road No. 10, Banjara Hills
Hyderabad - 500 034

T: +91 (40) 4424 6000, F: +91 (40) 4424 6300

Registered office and Head office: Sucheta Bhawan, 11A Vishnu Digambar Marg, New Delhi 110 002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

Price Waterhouse Chartered Accountants LLP

Opinion

6. In our opinion and to the best of our information and according to the explanations given to us:
 - (i) the Statement, together with the notes thereon are presented in the format prescribed under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
 - (ii) the Annual audited standalone financial results for the year ended March 31, 2019 as set out in the Statement gives a true and fair view of the total comprehensive income (comprising of profit and other comprehensive income), and other financial information of the Company for the year ended March 31, 2019 in accordance with the accounting principles generally accepted in India.

Emphasis of Matter

7. We draw your attention to Note 5 of the Statement regarding the figures for the quarter ended March 31, 2019, which are the balancing figures between audited figures in respect of the full financial year and the published year-to-date figures up to the third quarter of the current financial year. Our opinion is not qualified in respect of this matter.

Other Matter

8. The Statement dealt with by this report has been prepared for the express purpose of filing with National stock exchange of India Limited and BSE Limited. This Statement is based on and should be read with the audited financial statements of the company for the year ended March 31, 2019 on which we issued an unmodified audit opinion vide our report dated May 25, 2019.

Restriction on Use

9. This report is addressed to the Board of Directors of the Company and has been prepared for and only for the purposes set out in paragraph 8 above. This report should not be otherwise used by any other party for any other purpose.

For Price Waterhouse Chartered Accountants LLP
Firm Registration No. 012754N/N500016




Sunit Kumar Basu
Partner
Membership No:55000

Place: Hyderabad
Date: May 25, 2019

DIVI'S LABORATORIES LIMITED

STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH, 2019

Particulars		Year ended	
		31.03.2019	31.03.2018
		(Audited)	(Audited)
1	Revenue from operations	494626	391278
2	Other Income	15563	11344
3	Total Revenue from Operations (1+2)	510189	402622
4	Expenses		
	a) Cost of materials consumed	210389	152857
	b) Purchase of stock-in-trade	2592	216
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(30459)	333
	d) Employee benefits expense	54227	45606
	e) Depreciation and amortization expense	16890	14249
	f) Finance Costs	350	133
	g) Other Expenses	70693	66095
	Total expenses	324682	279489
5	Profit before exceptional Items and tax (3-4)	185507	123133
6	Exceptional items	0	0
7	Profit before Tax (5-6)	185507	123133
8	Tax Expense		
	a) Current Tax	47551	28983
	b) Deferred Tax	2682	6449
	Total Tax Expense	50233	35432
9	Net Profit for the period (7-8)	135274	87701
10	Other Comprehensive Income:		
	a) Items that will not be reclassified to Profit or Loss:		
	- Remeasurement of post-employment benefit obligations	141	94
	b) Items that will be reclassified to Profit or Loss:		
	Exchange differences in translating the financial statements of a foreign operation	(140)	923
	Income tax relating to OCI	(36)	(27)
	Other comprehensive Income after tax for the year	(35)	990
11	Total comprehensive Income for the period (9-10)	135239	88691
12	Paid-up Equity Share Capital (Face Value: Rs.2 per share)	5309	5309
13	Other Equity	690406	587171
14	Earnings per Share (of Rs.2/- each) (not annualized)		
	a) Basic (Rs.)	50.96	33.04
	b) Diluted (Rs.)	50.96	33.04



Statement of Assets and Liabilities

(₹. in lakhs)

	Particulars	CONSOLIDATED	
		As At	
		31.03.2019	31.03.2018
		Audited	Audited
A	ASSETS		
1	Non-current assets		
	Property, plant and equipment	208372	198964
	Capital work-in-progress	49191	11976
	Intangible assets	405	655
	Financial assets		
	a) Investments	54726	1
	b) Loans	3404	3413
	Income Tax Asset (net)	1928	881
	Deferred tax asset (net)	234	103
	Other non-current assets	20560	9080
	Sub-total: Non-current assets	338820	225073
2	Current assets		
	Inventories	177234	135067
	Financial assets		
	a) Investments	139834	188928
	b) Trade receivables	116337	101436
	c) Cash and cash equivalents	1300	2515
	d) Bank balances other than c) above	10226	8731
	e) Loans	11	17
	f) Other financial assets	135	948
	Other current assets	19928	15870
	Sub-total: Current assets	465005	453512
	TOTAL ASSETS	803825	678585
B	EQUITY AND LIABILITIES		
1	Equity:		
	Share Capital	5309	5309
	Other Equity:		
	(i) Reserves and surplus	689623	586248
	(ii) Other Equity	783	923
	Sub-total: Shareholders' funds	695715	592480
2	Liabilities:		
	Non-current liabilities		
	Financial liabilities		
	a) Provisions	1317	1495
	b) Deferred tax liabilities (net)	22118	19268
	Sub-total: Non-current liabilities	23435	20763
3	Current Liabilities		
	Financial liabilities		
	a) Borrowings	10560	6311
	b) Trade payables	49226	41121
	(c) Other financial liabilities	6289	2233
	Provisions	111	94
	Current tax liabilities (net)	419	270
	Other current liabilities	18070	15313
	Sub-total: Current liabilities	84675	65342
	Total Liabilities	108110	86105
	TOTAL EQUITY AND LIABILITIES	803825	678585



NOTES:

1. The above audited Consolidated results for the quarter and year ended 31st March 2019, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 25th May, 2019 and the same have been audited by the Statutory auditors in compliance with regulation 33 of SEBI (Listing of Obligation and Disclosure Requirement) Regulation 2015. The Statutory Auditors report contains no qualification.
2. The consolidated results include the audited financial results of the subsidiaries Divis Laboratories (USA) Inc and Divi's Laboratories Europe AG.
3. The Company is engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates and the same constitutes a single reportable business segment as per Ind AS 108.
4. These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
5. Post implementation of Goods and Service Tax (GST) effective from 1st July, 2017, revenue is reported net of GST as per Ind AS 18/115. Revenue, however, is reported inclusive of excise duty for a part of the year ended 31st March, 2018. Had the previously reported revenue been shown net of excise duty, comparative revenue of the company would have been as under:

(₹. in lakhs)

Particulars	Year Ended	
	31.03.2019	31.03.2018
	(Audited)	(Audited)
Revenue from operations (net of excise duty)	494626	389291

6. Details of forex gain/loss are given below:

(₹. in lakhs)

Particulars	Year Ended	
	31.03.2019	31.03.2018
	(Audited)	(Audited)
Forex gain/(loss)	3086	2795

Forex gain has been included in Other Income and loss has been included in Other Expenses

7. Figures for the previous year/period have been reclassified/ regrouped wherever necessary to conform to current year's classification.

Place: Hyderabad
Date: 25-05-2019



for Divi's Laboratories Limited


Dr. Murali K. Divi
Chairman & Managing Director



Price Waterhouse Chartered Accountants LLP

The Board of Directors
Divi's Laboratories Limited
Divi Towers, 1-72/23(P)/Divis/303,
Cyber Hills, Gachibowli,
Hyderabad- 500 032

Independent Auditor's Report on the Statement of consolidated financial results

1. We have audited the accompanying Statement containing the annual audited consolidated financial results of Divi's Laboratories Limited ("hereinafter referred to as the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), (refer Note 2 to the consolidated financial results) for the year ended March 31, 2019 together with the notes thereon (hereinafter referred to as the "Statement"), which we have signed under reference to this report.

Management's Responsibility for the consolidated financial results

2. Management of the Holding Company is responsible for the preparation of the accompanying Statement. The Management is also responsible for the preparation of the annual statutory consolidated financial statements in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 (the "accounting principles generally accepted in India"), basis which the above Statement containing the annual audited consolidated financial results has been prepared. The responsibility includes the design, implementation and maintenance of internal control relevant to the preparation of the Statement that is free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

3. Our responsibility is to express an opinion on the Statement based on our audit. We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 ("the Act") and other applicable authoritative pronouncements issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.
4. An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the Statement. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditors consider internal control relevant to the entity's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by Management, as well as evaluating the overall presentation of the Statement.
5. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



Price Waterhouse Chartered Accountants LLP, Plot No. 77/A, 8-2-624/A/1, 3rd Floor, Road No. 10, Banjara Hills
Hyderabad - 500 034

T: +91 (40) 4424 6000, F: +91 (40) 4424 6300

Registered office and Head office: Sucheta Bhawan, 11A Vishnu Digambar Marg, New Delhi 110 002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

Price Waterhouse Chartered Accountants LLP

Opinion

6. In our opinion and to the best of our information and according to the explanations given to us:
- (i) the Statement, together with the notes thereon are presented in the format prescribed under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
 - (ii) the Annual audited consolidated financial results for the year ended March 31, 2019 as set out in the Statement gives a true and fair view of the total consolidated comprehensive income (comprising of consolidated profit and consolidated other comprehensive loss), and other financial information of the Group for the year ended March 31, 2019 in accordance with the accounting principles generally accepted in India.

Other Matter

7. The Statement dealt with by this report has been prepared for the express purpose of filing with National stock exchange of India Limited and BSE Limited. This Statement is based on and should be read with the audited consolidated financial statements of the group, for the year ended March 31, 2019 on which we issued an unmodified audit opinion vide our report dated May 25, 2019

Restriction on Use

8. This report is addressed to the Board of Directors of the Holding Company and has been prepared for and only for the purposes set out in paragraph 7 above. This report should not be otherwise used by any other party for any other purpose.

For Price Waterhouse Chartered Accountants LLP
Firm Registration No.012547N/N500016



Sunit Kumar Basu
Partner
Membership No: 55000

Place: Hyderabad
Date: May 25, 2019



Divi's Laboratories Limited

Date: 25th May 2019

To
The Secretary
National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex, Bandra (East)
MUMBAI - 400 051

Stock Code: DIVISLAB

To
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
MUMBAI - 400 001

Stock Code: 532488

Dear Sir,

Sub: Declaration regarding Audit Reports with unmodified opinion

Ref: Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015

With reference to the above, we hereby declare that the Statutory Auditors of the Company, have issued Audit Reports with Unmodified Opinion on the Audited Standalone and Consolidated Financial results for the year ended 31st March 2019.

This is for your information and records.

Thanking You,

Yours faithfully,
For Divi's Laboratories Limited

L. Kishore Babu
Chief Financial Officer



“An ISO-9001, ISO-14001 and OHSAS-18001 Triple certified company”

Regd. Off. : Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, INDIA.

Tel : 91-40-2378 6300, Fax : 91-40-2378 6460, CIN : L24110TG1990PLC011854

E-mail : mail@divislaboratories.com, Website : www.divislaboratories.com

DIVI'S LABORATORIES LIMITED
1-72/23(P)/DIVIS/303. Divi Towers
Cyber Hills, Gachibowli, Hyderabad 500 032
Phone: 91-40-23786300 email: kishore@divislabs.com

PRESS RELEASE dated 25th May, 2019

Divi's Labs earns a Revenue of ₹. 5102 crores for FY19 on consolidated basis.

Consolidated for the year

For the year, Divi's Laboratories has earned a consolidated total revenue of ₹. 5102 crores for the financial year 2018-19 as against ₹. 4026 crores during the previous year, reflecting a growth of 27%.

PBT for the current year came to ₹. 1855 crores as against a PBT of ₹. 1231 crores for the previous year reflecting a growth of 51%. PAT for the year grew by 54% to ₹. 1353 crores as against a PAT of ₹. 877 crores for the last year.

Standalone Results

On a standalone basis, the company's earnings are as given below:

₹. in crores

Particulars	For the Quarter		For the year	
	31-03-19	31-03-18	31-03-19	31-03-18
Total Revenue	1298	1136	5036	3950
PBT	410	396	1833	1219
PAT	289	262	1333	870

Forex Gain/(loss)

Particulars of forex gain/(loss) for the period are given below:

₹. in crores

Particulars	For the Quarter ended		For the year ended	
	31-03-19	31-03-18	31-03-19	31-03-18
Forex gain/(loss)	(7)	23	31	25



Dividend

The Board has recommended a dividend of ₹.16 per share i.e., 800% for the year subject to approval of members.

Capex:

In order to cater to the increasing opportunities in generic and big pharma business, the company is taking up the following expansion programs with an aggregate investment of Rs.1690 crores:

- A brownfield SEZ Unit at our Unit-2 near Visakhapatnam, named as DCV SEZ Unit, with an investment of ₹. 600 crores. (revised from the estimate of ₹. 400 crores announced at the last General Meeting).
- Another SEZ Project at our Unit-1 near Hyderabad, called Chandra SEZ with an investment of ₹. 600 crores.
- Debottlenecking programs at Unit-1 as well as Unit-2 with an aggregate investment of ₹. 300 crores.
- An expansion program and modernization of the utilities at our EOU unit with an investments of Rs.190 cr.

Work has already commenced and these Projects are expected to be completed by end of the year 2019-20 barring unforeseen circumstances.



A handwritten signature in blue ink is positioned to the left of a circular blue stamp. The stamp contains the text "DANI'S LABORATORIES LTD." around the top inner edge, "HYDERABAD-32" in the center, and "GACHIBOWLI" around the bottom inner edge, flanked by two small stars.